The anti-müllerian hormone (AMH) is responsible for regression of müllerian ducts during male sexual differentiation. Mutations in the AMH gene or its type II receptor gene AMHR2 lead to persistence of the uterus and fallopian tubes in male children, i.e. persistent müllerian duct syndrome (PMDS). Both conditions are transmitted according to an autosomal recessive pattern and are symptomatic only in males. We report on 2 unrelated Egyptian consanguineous families with PMDS. The first family comprised 3 affected prepubertal sibs complaining of undescended testes. Pelvic exploration and laparotomy revealed müllerian duct derivatives. The other family was presenting with an adolescent male with impalpable left testis, and pelvic exploration showed remnants of fallopian tubes and rudimentary uterus. AMH levels were very low and almost undetectable in all affected patients in both families. Direct sequencing of the coding region of the AMH gene identified 2 homozygous mutations in exon 1, R95X in the first family and V12G in the second family. These data confirmed the autosomal recessive type of PMDS. Molecular investigation of this rare disorder in a larger number of cases with undescended testes in Egypt is warranted for proper diagnosis and genetic counseling.

1.
Belville C, Josso N, Picard JY: Persistence of müllerian derivatives in males. Am J Med Genet 89:218–223 (1999).
2.
Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, et al: Isolation of the bovine and human genes for müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45:685–698 (1986).
3.
Cohen-Haguenauer O, Picard JY, Mattei MG, Serero S, Nguyen VC, et al: Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 44:2–6 (1987).
4.
Hutson JM, Hasthorpe S, Heyns CF: Anatomical and functional aspects of testicular descent and cryptorchidism. Endocr Rev 18:259–280 (1997).
5.
Imbeaud S, Carré-Eusèbe D, Rey R, Belville C, Josso N, Picard JY: Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families. Hum Mol Genet 3:125–131 (1994).
6.
Imbeaud S, Rey R, Berta P, Chaussain JL, Wit JM, et al: Testicular degeneration in three patients with the persistent müllerian duct syndrome. Eur J Pediatr 154:187–190 (1995).
7.
Josso N, Picard JY, Imbeaud S, di Clemente N, Rey R: Clinical aspects and molecular genetics of the persistent müllerian duct syndrome. Clin Endocrinol (Oxf) 47:137–144 (1997).
8.
Josso N, Belville C, di Clemente N, Picard JY: AMH and AMH receptor defects in persistent müllerian duct syndrome. Hum Reprod Update 11:351–356 (2005).
9.
Knebelmann B, Boussin L, Guerrier D, Legeai L, Kahn A, et al: Anti-müllerian hormone Bruxelles: a nonsense mutation associated with the persistent müllerian duct syndrome. Proc Natl Acad Sci USA 88:3767–3771 (1991).
10.
Lang-Muritano M, Biason-Lauber A, Gitzelmann C, Belville C, Picard Y, Schoenle EJ: A novel mutation in the anti-müllerian hormone gene as cause of persistent müllerian duct syndrome. Eur J Pediatr 160:652–654 (2001).
11.
Menabò S, Balsamo A, Nicoletti A, Gennari M, Pirazzoli P, et al: Three novel AMH gene mutations in a patient with persistent müllerian duct syndrome and normal AMH serum dosage. Horm Res 70:124–128 (2008).
12.
Rey R: Anti-müllerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol 49:26–36 (2005).
13.
Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK: Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology 140:4732–4738 (1999).
14.
Von Heijne G: Patterns of amino acids near signal-sequence cleavage sites. Eur J Biochem133:17–21 (1983).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.